Form 4: Plus Therapeutics Director Reports RSU Vesting

Plus Therapeutics, Inc. director An van Es-Johansson reported the vesting of 922 Restricted Stock Units (RSUs) on July 1, 2026.

Summary

• An van Es-Johansson, a Director at Plus Therapeutics, Inc., reported a transaction on July 1, 2026.
• The transaction involved the vesting of 922 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of the issuer's Common Stock.
• The vesting of these RSUs occurs in four substantially equal quarterly installments, with the first installment on July 1, 2026.
• Following this transaction, van Es-Johansson beneficially owns 922 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine RSU vesting event for a director and does not indicate new strategic information or significant financial changes.

Positives

• Director An van Es-Johansson's RSU grant is vesting as scheduled, indicating continued commitment and alignment with the company's performance.
• The vesting schedule suggests a structured incentive program for key personnel.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, reflecting normal compensation and incentive structures within the biotechnology sector.

Stakeholder Impact

• Shareholders: The vesting of RSUs is a standard compensation practice and is unlikely to have a significant immediate impact on the share price, but it reflects ongoing incentive alignment.

Next Steps

• Continued quarterly vesting of RSUs as per the grant agreement.

Key Dates

Keywords

Plus Therapeutics, PSTV, Form 4, RSU Vesting, Director, Beneficial Ownership, Securities Exchange Act